You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 202 No. 9, November 27, 1967 TABLE OF CONTENTS
  JAMA
  •  Online Features
  PRELIMINARY COMMUNICATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

L-Asparaginase Therapy for Leukemia and Other Malignant Neoplasms

Remission in Human Leukemia

Joseph M. Hill, MD; Joseph Roberts, PhD; Ellen Loeb, MD; Amanullah Khan, MD; Ayten MacLellan, MD; Robert W. Hill, MD

JAMA. 1967;202(9):882-888.


Abstract

Enzyme therapy directed at depletion of an amino acid, asparagine, indispensable for tumor cell growth but not required by normal tissues, offers a new and promising approach to the problem of treatment of leukemia and disseminated cancer. Therapy with the enzyme L-asparaginase in three cases of acute lymphatic leukemia resulted in measurable improvement in two advanced cases. In the third case, there was a striking response to large dosage, with rapid necrosis of lymph node masses and clearing of leukemic infiltrates. A laboratory test to detect dependency of tumor cells on asparagine seems helpful for selection of cases for investigation of therapy. Furthermore, a variety of human malignant diseases including acute lymphatic leukemia and acute and chronic granulocytic leukemia have been shown to be asparagine-dependent by this test. Exploitation of further possible nutritional differences offers a fertile field for investigation.



Author Affiliations

From the Wadley Institutes of Molecular Medicine, Dallas.


Footnotes

Read before the Acute Leukemia Task Force of the National Institutes of Health, Washington, DC, May 15, 1967.

Reprint requests to 3600 Gaston Ave, Dallas 75246 (Dr. Hill).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

GCN2 Protein Kinase Is Required to Activate Amino Acid Deprivation Responses in Mice Treated with the Anti-cancer Agent L-Asparaginase
Bunpo et al.
J. Biol. Chem. 2009;284:32742-32749.
ABSTRACT | FULL TEXT  

Role of Glutamine Depletion in Directing Tissue-specific Nutrient Stress Responses to L-Asparaginase
Reinert et al.
J. Biol. Chem. 2006;281:31222-31233.
ABSTRACT | FULL TEXT  

Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia
Parsons et al.
Blood 1997;89:1886-1895.
ABSTRACT | FULL TEXT  

L-Asparaginase: Clinical, Biochemical, Pharmacological, and Immunological Studies
CAPIZZI et al.
ANN INTERN MED 1971;74:893-901.
ABSTRACT  

Low-Dosage Asparaginase Treatment of Childhood Acute Lymphocytic Leukemia
Pratt et al.
Arch Pediatr Adolesc Med 1971;121:406-409.
ABSTRACT  

L-Asparaginase-Induced Immunosuppression: Effects on Antibody-Forming Cells and Serum Titers
Chakrabarty and Friedman
Science 1970;167:869-870.
ABSTRACT  

Effects of L-Asparaginase in Acute Myelocytic Leukemia
Ohnuma et al.
JAMA 1969;210:1919-1921.
ABSTRACT  

Asparagine Synthetase Activity of Mouse Leukemias
Horowitz et al.
Science 1968;160:533-535.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1967 American Medical Association. All Rights Reserved.